CLOSING HELD FOR ACQUISITION OF NEUROVIR THERAPEUTICS, INC.
MediGene AG is acquiring NeuroVir in a stock-for-stock transaction. 996.631 new MediGene AG shares will be issued to NeuroVir’s shareholders, with an exclusion of pre-emptive rights of existing shareholders, in exchange for all shares of NeuroVir that MediGene had not already owned. MediGene AG purchased approximately 9% of NeuroVir previously to its IPO in June 2000. Upon completion of the transaction, NeuroVir’s former shareholders will hold approximately 8.6% of MediGene AG ‘s outstanding shares on a fully diluted basis.
“We are proud to have completed this important strategic step, and will ardently pursue the integration of the new MediGene, Inc. into the combined entity," states MediGene’s CEO, Peter Heinrich, Ph.D. “The merger adds two product candidates in clinical development and one platform technology to our product and technology portfolio and enhances potential peak sales by US$ 500 million. With the broadened range of product candidates and technologies MediGene now further reduces the risk profile of the company. In addition the transaction establishes a foothold for MediGene in the US, we now benefit of former NeuroVir’s experience with the FDA, their extensive clinical network, and their Scientific Advisory Board including outstanding international scientists and opinion leaders.“
With this acquisition, MediGene has five product candidates in clinical development: Polyphenon™E against genital warts (phase 3), Etomoxir against Congestive Heart Failure (phase 2), G207 to treat malignant brain tumors (phase 2 in preparation), NV1020 to treat colorectal cancer that has metastasized to the liver (phase 1/2) and CVLP vaccine to treat cervical cancer and its precursors (phase 1/2). Its technology platform comprises four proprietary technologies applied in cardiology and oncology.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.